<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848769</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0902-PR-0013</org_study_id>
    <nct_id>NCT01848769</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old</brief_title>
  <acronym>PAED1</acronym>
  <official_title>A Single-dose, Open-Label, 2-Way Cross-Over, Clinical Pharmacology Study Of Chf 1535 50/6 HFA pMDI (Fixed Combination Of Beclomethasone Dipropionate 50µg Plus Formoterol Fumarate 6 µg) Using The Aerochamber Plus™ Spacer Device Versus The Free Combination Of Beclomethasone HFA pMDI And Formoterol HFA pMDI Available On The Market Using The Aerochamber Plus™ Spacer Device In Asthmatic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale is to investigate the systemic availability of BDP/B17MP and formoterol after
      single oral inhalation of CHF 1535 50/6 pMDI vs the free combination of approved BDP and
      Formoterol pMDIs, in asthmatic children (5 to 11 years old).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>B17MP AUC0-t</measure>
    <time_frame>pre-dose until 8hours post dose</time_frame>
    <description>B17MP (active metabolite of BDP) systemic exposure as AUC0-t</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B17MP PK profile</measure>
    <time_frame>pre-dose until 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP PK prolile</measure>
    <time_frame>Pre-dose until 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formoterol PK profile</measure>
    <time_frame>Pre-dose until 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium AUC, Cmin, tmin</measure>
    <time_frame>Pre-dose until 8 hours post-dose</time_frame>
    <description>Plasma potassium to evaluate drug systemic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Cortisol excretion</measure>
    <time_frame>Pre-dose until 8 hours post-dose</time_frame>
    <description>8h urinary excretion of cortisol and 8h urinary excretion of cortisol normalized for 8h creatinine excretion to evaluate dru systemic effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose in urine</measure>
    <time_frame>Pre-dose until 8 hours post-dose</time_frame>
    <description>Glucose to evaluate the drug systemic effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate Time averaged heart rate value (AUC0-t)/t</measure>
    <time_frame>Pre-dose until 8 hours post-dose</time_frame>
    <description>Heart rate to evaluate the drug systemic effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry: PEF</measure>
    <time_frame>Pre-dose until 8 hours post-dose</time_frame>
    <description>Peak respiratory flow as a measure of drug efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF1535 pMDI + AC Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP and Formoterol + AC Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 pMDI + AC Plus</intervention_name>
    <description>Four inhalations for a total dose of BDP/FF 200/24 mcg</description>
    <arm_group_label>CHF1535 pMDI + AC Plus</arm_group_label>
    <other_name>Fixed combination of BDP and FF 50/6 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP + AC Plus</intervention_name>
    <description>Four inhalations for a total dose of BDP 200 mcg</description>
    <arm_group_label>BDP and Formoterol + AC Plus</arm_group_label>
    <other_name>Beclomethasone Dipropionate 50 mcg with Aerochamber Plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol + AC Plus</intervention_name>
    <description>Four inhalations for a total dose of Formoterol 24 mcg</description>
    <arm_group_label>BDP and Formoterol + AC Plus</arm_group_label>
    <other_name>Formoterol 6 mcg with Aerochamebr Plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female children aged 5-11 years

          -  Written informed consent obtained by parents/legal representative (according to local
             regulation) and by the minor (age and local regulation permitting).

          -  children with stable asthma on regular treatment with ICS or using short-acting
             inhaled beta2-agonists as reliever to control asthma symptoms

          -  Forced expiratory volume in one second (FEV1) &gt; 70% of predicted values (% pred) after
             withholding beta2-agonist treatment for a minimum of 4 h prior to each dose period.

             6. A cooperative attitude and ability to be trained about the proper use of pMDI with
             a spacer device and compliant to study procedures.

        Exclusion Criteria:

          -  Past or present diagnoses of cardiovascular, renal or liver disease

          -  Known hypersensitivity to the active treatments

          -  Exacerbation of asthma symptoms within the previous 4 weeks

          -  Inability to perform the required breathing technique and blood sampling

          -  Hospitalization due to exacerbation of asthma within 1 month prior to inclusion

          -  Lower respiratory tract infection within 1 month prior to inclusion

          -  Disease (other than asthma) which might influence the outcome of the study

          -  Obesity, i.e. &gt; 97% weight percentile by local standards
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Bisgaard, MD DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>BorneAstmaKlinikken</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BorneAstmaKlinikken</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010434-22</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Chawes BL, Piccinno A, Kreiner-Møller E, Vissing NH, Poorisrisak P, Mortensen L, Nilson E, Bisgaard A, Dossing A, Deleuran M, Skytt NL, Samandari N, Sergio F, Ciurlia G, Poli G, Acerbi D, Bisgaard H. Pharmacokinetic comparison of inhaled fixed combination vs. the free combination of beclomethasone and formoterol pMDIs in asthmatic children. Br J Clin Pharmacol. 2013 Apr;75(4):1081-8. doi: 10.1111/j.1365-2125.2012.04459.x.</citation>
    <PMID>22978252</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>ICS+LABA</keyword>
  <keyword>Children</keyword>
  <keyword>Inhalation</keyword>
  <keyword>pMDI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

